Bird – Page 2 – Talk Bio

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

HHS Awards Moderna $590 Million to Expedite Bird Flu Vaccine Development

8 months ago talkbio0Tagged Aves, CHARGE Syndrome, Moderna, mRNA Vaccine, pandemic preparedness, Vaccines

Moderna, HHS, Bird Flu Vaccine, Avian Influenza, mRNA Vaccine, Pandemic Preparedness

National Resilience Lays Off 120 Employees at Former Bluebird Bio Gene Therapy Facility in Durham, North Carolina

8 months ago talkbio0Tagged Bio, biotech industry, CDMO, Contract Development, Durham/, Family Turdidae (organism), gene therapy, layoffs, Manufacturing Organization, National Resilience, North Carolina

National Resilience, Layoffs, Gene Therapy, Bluebird Bio, Durham/ North Carolina, Biotech Industry, CDMO (Contract Development and Manufacturing Organization)

Aviceda Secures $200M Series C Funding to Advance Ocular Drug AVD-104 into Late-Stage Trials

8 months ago talkbio0Tagged Age related macular degeneration, AVD-104, Genus Aviceda, Geographic Atrophy, late-stage clinical trials, Macular edema due to diabetes mellitus, Series C

Aviceda Therapeutics, AVD-104, Geographic Atrophy, Age-Related Macular Degeneration, Diabetic Macular Edema, Series C Funding, Late-Stage Clinical Trials

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

9 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology

Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views

10 months ago talkbio0Tagged Administration occupational activities, Appointments, Bhattacharya, Controversial, COVID19 (disease), Critic, Jay, NIH Director Nomination, Pandemic Response, Professor, Public Health Research, Stanford University, Transplant Registry Unified Management Program

Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment

PTC Therapeutics Discontinues Utreloxastat Program Following Phase 2 ALS Trial Failure

10 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Cardinalis cardinalis, factor IX, Phase 2 trial, Utreloxastat

PTC Therapeutics, Utreloxastat, ALS, Phase 2 Trial, CardinALS Study, Amyotrophic Lateral Sclerosis